Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $14.6667.
ACHV has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Achieve Life Sciences in a report on Thursday, April 16th. Wall Street Zen upgraded shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday. Canaccord Genuity Group set a $13.00 target price on shares of Achieve Life Sciences and gave the company a “buy” rating in a report on Monday, April 20th. Finally, Weiss Ratings cut shares of Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th.
Get Our Latest Analysis on ACHV
Institutional Inflows and Outflows
Achieve Life Sciences Trading Down 9.8%
NASDAQ ACHV opened at $4.77 on Tuesday. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.87. Achieve Life Sciences has a 52 week low of $2.00 and a 52 week high of $6.15. The stock has a market capitalization of $253.91 million, a PE ratio of -4.26 and a beta of 2.25. The firm has a 50 day moving average of $4.08 and a two-hundred day moving average of $4.47.
Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.11. As a group, research analysts expect that Achieve Life Sciences will post -0.91 EPS for the current fiscal year.
About Achieve Life Sciences
Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.
Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.
Featured Articles
- Five stocks we like better than Achieve Life Sciences
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
